Ignite Creation Date:
2025-12-25 @ 2:39 AM
Ignite Modification Date:
2025-12-30 @ 10:28 AM
Study NCT ID:
NCT05044234
Status:
TERMINATED
Last Update Posted:
2023-11-29
First Post:
2021-09-07
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis
Sponsor:
AbbVie
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-11-16
Start Date Type:
ACTUAL
Primary Completion Date:
2022-11-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-11-30
Completion Date Type:
ACTUAL
First Submit Date:
2021-09-07
First Submit QC Date:
None
Study First Post Date:
2021-09-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-11-06
Results First Submit QC Date:
None
Results First Post Date:
2023-11-29
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-11-06
Last Update Post Date:
2023-11-29
Last Update Post Date Type:
ACTUAL